Proteasome structure, function, and lessons learned from beta-lactone inhibitors

Current Topics in Medicinal Chemistry

Volumn 11, Issue 23, 2011, Pages 2850-2878

  Groll, Michael ^a   Potts, Barbara C ^b,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Nereus Pharmaceuticals Inc   (United States)

^c CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

Beta lactone inhibitor; Cancer therapy; Drug design; Irreversible binding; Medicinal chemistry; Proteasome; Structure activity relationship; Ubiquitin pathway

Indexed keywords

BORTEZOMIB; BROMOSALINOSPORAMIDE; CALPAIN; CARFILZOMIB; CHLOROETHYLCLONIDINE; EPOXOMICIN; FLUORIDE; HYDROXYSALINOSPORAMIDE; IODOSALINOSPORAMIDE; LACTACYSTIN; LACTACYSTIN BETA LACTONE; LUOROSALINOSPORAMIDE; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SALINOSPORAMIDE B; SALINOSPORAMIDE D; THREONINE PROTEINASE INHIBITOR; UBIQUITIN; UNCLASSIFIED DRUG;

ACYLATION; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER INHIBITION; CATALYSIS; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CRYSTAL STRUCTURE; CYTOTOXICITY; DEACYLATION; DRUG BINDING; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HYDROGEN BOND; HYDROLYSIS; HYDROPHOBICITY; IC 50; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MUTAGENESIS; NEUROPROTECTION; NONHUMAN; PKA; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTON TRANSPORT; SIGNAL TRANSDUCTION; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION;

EID: 83455178837     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798281320     Document Type: Article

References (172)

1. Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem., 1998, 67, 425-479.
2. Borissenko, L.; Groll, M. Diversity of proteasomal missions: fine tuning of the immune response. Biol. Chem., 2007, 388, 947-955.
3. Groll, M.; Clausen, T. Molecular shredders: how proteasomes fulfill their role. Curr. Opin. Struct. Biol., 2003, 13, 665-673.
4. Groll, M.; Bochtler, M.; Brandstetter, H.; Clausen, T.; Huber, R. Molecular machines for protein degradation. ChemBioChem, 2005, 6, 222-256.
5. Deveraux, Q.; Ustrell, V.; Pickart, C.; Rechsteiner, M. A 26 S protease conjugates. J. Biol. Chem., 1994, 272, 182-188.
6. Kam, Y. A.; Xu, W.; Demartino, G. N.; Cohen, R. E. Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome. Nature, 1997, 385, 737-740.
7. Rubin, D. M.; Glickman, M. H.; Larsen, C. N.; Dhruvakumar, S.; Finley, D. Active site mutants in the six regulatory particle ATPases reveal multiple roles for ATP in the proteasome. EMBO J., 1998, 17, 4909-4919.
8. Braun, B. C.; Glickman, M.; Kraft, R.; Dahlmann, B.; Kloetzel, P. M.; Finley, D.; Schmidt, M. The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat. Cell Biol., 1999, 1, 221-226.
9. Dahlmann, B.; Kuehn, L.; Grziwa, A.; Zwickl, P.; Baumeister, W. Biochemical properties of the proteasome from Thermoplasma acidophilum. Eur. J. Biochem., 1992, 208, 789-797.
10. Ruepp, A.; Eckerskorn, C.; Bogyo, M.; Baumeister, W. Proteasome function is dispensable under normal but not under heat shock conditions in Thermoplasma acidophilum. FEBS Lett., 1998, 425, 87-90.
11. Voges, D.; Zwickl, P.; Baumeister, W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem., 1999, 68, 1015-1068.
12. Prudhomme, J.; McDaniel, E.; Ponts, N.; Bertani, S.; Fenical, W.; Jensen, P.; Le Roch, K. Marine actinomycetes: a new source of compounds against the human malaria parasite. PLoS One, 2008, 3, e2335.
13. Skaug, B.; Jiang, X.; Chen, Z. J. The role of ubiquitin in NFkappaB regulatory pathways. Annu. Rev. Biochem., 2009, 78, 769-796.
14. Chen, J. J.; Lin, F.; Qin, Z. H. The roles of the proteasome pathway in signal transduction and neurodegenerative diseases. Neurosci. Bull., 2008, 24, 183-194.
15. Dahlmann, B. Role of proteasomes in disease. BMC Biochem., 2007, 8 (Suppl 1), S3.
16. Shah, J. J.; Orlowski, R. Z. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia, 2009, 23, 1964-1979.
17. Richardson, P. G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S. V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R. Z.; Kuter, D.; Limentani, S. A.; Lee, S.; Hideshima, T.; Esseltine, D. L.; Kauffman, M.; Adams, J.; Schenkein, D. P.; Anderson, K. C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med., 2003, 348, 2609-2617.
18. Bross, P. F.; Kane, R.; Farrell, A. T.; Abraham, S.; Benson, K.; Brower, M. E.; Bradley, S.; Gobburu, J. V.; Goheer, A.; Lee, S. L.; Leighton, J.; Liang, C. Y.; Lostritto, R. T.; McGuinn, W. D.; Morse, D. E.; Rahman, A.; Rosario, L. A.; Verbois, S. L.; Williams, G.; Wang, Y. C.; Pazdur, R. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin. Cancer Res., 2004, 10, 3954-3964.
19. Feling, R. H.; Buchanan, G. O.; Mincer, T. J.; Kauffman, C. A.; Jensen, P. R.; Fenical, W. Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew. Chem. Int. Ed. Engl., 2003, 42, 355-357.
20. Fenical, W.; Jensen, P. R.; Palladino, M. A.; Lam, K. S.; Lloyd, G. K.; Potts, B. C. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg. Med. Chem., 2009, 17, 2175-2180.
21. Hegerl, R.; Pfeifer, G.; Puhler, G.; Dahlmann, B.; Baumeister, W. The three-dimensional structure of proteasomes from Thermoplasma acidophilum as determined by electron microscopy using random conical tilting. FEBS Lett., 1991, 283, 117-121.
22. Löwe, J.; Stock, D.; Jap, B.; Zwickl, P.; Baumeister, W.; Huber, R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science, 1995, 268, 533-539.
23. Groll, M.; Ditzel, L.; Lowe, J.; Stock, D.; Bochtler, M.; Bartunik, H. D.; Huber, R. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature, 1997, 386, 463-471.
24. Unno, M.; Mizushima, T.; Morimoto, Y.; Tomisugi, Y.; Tanaka, K.; Yasuoka, N.; Tsukihara, T. The structure of the mammalian 20S proteasome at 2.75 Å resolution. Structure, 2002, 10, 609-618.
25. Bochtler, M.; Ditzel, L.; Groll, M.; Huber, R., Crystal structure of heat shock locus V (HslV) from Escherichia coli. Proc. Natl. Acad. Sci. USA, 1997, 94, 6070-6074.
26. Sousa, M.; McKay, D. Structure of Haemophilus influenzae HslV protein at 1.9 A resolution, revealing a cation-binding site near the catalytic site. Acta Crystallogr. D Biol. Crystallogr., 2001, 57, 1950-1954.
27. Borissenko, L.; Groll, M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem. Rev., 2007, 107, 687-717.
28. Heinemeyer, W.; Trondle, N.; Albrecht, G.; Wolf, D. H. PRE5 and PRE6, the last missing genes encoding 20S proteasome subunits from yeast? Indication for a set of 14 different subunits in the eukaryotic proteasome core. Biochemistry, 1994, 33, 12229-12237.
29. Heinemeyer, W.; Gruhler, A.; Mohrle, V.; Mahe, Y.; Wolf, D. H. PRE2, highly homologous to the human major histocompatibility complex-linked RING10 gene, codes for a yeast proteasome subunit necessary for chrymotryptic activity and degradation of ubiquitinated proteins. J. Biol. Chem., 1993, 268, 5115-5120.
30. Groll, M.; Heinemeyer, W.; Jager, S.; Ullrich, T.; Bochtler, M.; Wolf, D. H.; Huber, R. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc. Natl. Acad. Sci. USA, 1999, 96, 10976-10983.
31. Jäger, S.; Groll, M.; Huber, R.; Wolf, D. H.; Heinemeyer, W. Proteasome beta-type subunits: unequal roles of propeptides in core particle maturation and a hierarchy of active site function. J. Mol. Biol., 1999, 291, 997-1013.
32. Heinemeyer, W.; Fischer, M.; Krimmer, T.; Stachon, U.; Wolf, D. H. The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J. Biol. Chem., 1997, 272, 25200-25209.
33. Manam, R. R.; McArthur, K. A.; Chao, T. H.; Weiss, J.; Ali, J. A.; Palombella, V. J.; Groll, M.; Lloyd, G. K.; Palladino, M. A.; Neuteboom, S. T.; Macherla, V. R.; Potts, B. C. Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides. J. Med. Chem., 2008, 51, 6711-6724.
34. Brown, M. G.; Driscoll, J.; Monaco, J. J. Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes. Nature, 1991, 353, 355-357.
35. Ortiz-Navarrete, V.; Seelig, A.; Gernold, M.; Frentzel, S.; Kloetzel, P. M.; Hammerling, G. J. Subunit of the '20S' proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex. Nature, 1991, 353, 662-664.
36. Frentzel, S.; Graf, U.; Hammerling, G. J.; Kloetzel, P. M. Isolation and characterization of the MHC linked beta-type proteasome subunit MC13 cDNA. FEBS Lett., 1992, 302, 121-125.
37. Yang, Y.; Waters, J. B.; Fruh, K.; Peterson, P. A. Proteasomes are regulated by interferon gamma: implications for antigen processing. Proc. Natl. Acad. Sci. USA, 1992, 89, 4928-4932.
38. Gaczynska, M.; Rock, K. L.; Goldberg, A. L. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature, 1993, 365, 264-267.
39. Aki, M.; Shimbara, N.; Takashina, M.; Akiyama, K.; Kagawa, S.; Tamura, T.; Tanahashi, N.; Yoshimura, T.; Tanaka, K.; Ichihara, A. Interferon-gamma induces different subunit organizations and functional diversity of proteasomes. J. Biochem. (Tokyo), 1994, 115, 257-269.
40. Akiyama, K.; Kagawa, S.; Tamura, T.; Shimbara, N.; Takashina, M.; Kristensen, P.; Hendil, K. B.; Tanaka, K.; Ichihara, A. Replacement of proteasome subunits X and Y by LMP7 and LMP2 induced by interferon-gamma for acquirement of the functional diversity responsible for antigen processing. FEBS Lett., 1994, 343, 85-88.
41. Parlati, F.; Lee, S. J.; Aujay, M.; Suzuki, E.; Levitsky, K.; Lorens, J. B.; Micklem, D. R.; Ruurs, P.; Sylvain, C.; Lu, Y.; Shenk, K. D.; Bennett, M. K. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood, 2009, 114, 3439-3447.
42. Orlowski, M.; Cardozo, C.; Michaud, C. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry, 1993, 32, 1563-1572.
43. Nussbaum, A. K.; Dick, T. P.; Keilholz, W.; Schirle, M.; Stevanovic, S.; Dietz, K.; Heinemeyer, W.; Groll, M.; Wolf, D. H.; Huber, R.; Rammensee, H. G.; Schild, H. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc. Natl. Acad. Sci. USA, 1998, 95, 12504-12509.
44. Ditzel, L.; Huber, R.; Mann, K.; Heinemeyer, W.; Wolf, D. H.; Groll, M. Conformational constraints for protein self-cleavage in the proteasome. J. Mol. Biol., 1998, 279, 1187-1191.
45. Groll, M.; Brandstetter, H.; Bartunik, H.; Bourenkow, G.; Huber, R. Investigations on the maturation and regulation of archaebacterial proteasomes. J. Mol. Biol., 2003, 327, 75-83.
46. Kwon, Y.; Nagy, I.; Adams, P.; Baumeister, W.; Jap, B. Crystal structures of the Rhodococcus proteasome with and without its propeptides: implications for the role of the pro-peptide in proteasome assembly. J. Mol. Biol., 2004, 335, 233-245.
47. Groll, M.; Bajorek, M.; Kohler, A.; Moroder, L.; Rubin, D. M.; Huber, R.; Glickman, M. H.; Finley, D. A gated channel into the proteasome core particle. Nat. Struct. Biol., 2000, 7, 1062-1067.
48. Whitby, F. G.; Masters, E. I.; Kramer, L.; Knowlton, J. R.; Yao, Y.; Wang, C. C.; Hill, C. P. Structural basis for the activation of 20S proteasomes by 11S regulators. Nature, 2000, 408, 115-120.
49. Rawlings, N. D.; Barrett, A. J. Families of serine peptidases. Methods Enzymol., 1994, 244, 19-61.
50. Davie, E. W.; Neurath, H. Identification of the peptide split from trypsinogen during autocatalytic activation. Biochim. Biophys. Acta, 1953, 11, 442.
51. Katunuma, N.; Fukusen, N.; Kido, H. Biological functions of serine proteases in the granules of rat mast cells. Adv. Enzyme Regul., 1986, 25, 241-255.
52. Pereira, P. J.; Bergner, A.; Macedo-Ribeiro, S.; Huber, R.; Matschiner, G.; Fritz, H.; Sommerhoff, C. P.; Bode, W. Human beta-tryptase is a ring-like tetramer with active sites facing a central pore. Nature, 1998, 392, 306-311.
53. Larsen, C. N.; Finley, D. Protein translocation channels in the proteasome and other proteases. Cell, 1997, 91, 431-434.
54. Heinemeyer, W.; Kleinschmidt, J. A.; Saidowsky, J.; Escher, C.; Wolf, D. H. Proteinase yscE, the yeast proteasome/multicatalyticmultifunctional proteinase: mutants unravel its function in stress induced proteolysis and uncover its necessity for cell survival. EMBO J., 1991, 10, 555-562.
55. Seemüller, E.; Lupas, A.; Stock, D.; Löwe, J.; Huber, R.; Baumeister, W. Proteasome from Thermoplasma acidophilum: a threonine protease. Science, 1995, 268, 579-582.
56. Seemüller, E.; Lupas, A.; Zuhl, F.; Zwickl, P.; Baumeister, W. The proteasome from Thermoplasma acidophilum is neither a cysteine nor a serine protease. FEBS Lett., 1995, 359, 173-178.
57. Fenteany, G.; Standaert, R. F.; Lane, W. S.; Choi, S.; Corey, E. J.; Schreiber, S. L. Inhibition of proteasome activities and subunitspecific amino-terminal threonine modification by lactacystin. Science, 1995, 268, 726-731.
58. Brannigan, J. A.; Dodson, G.; Duggleby, H. J.; Moody, P. C.; Smith, J. L.; Tomchick, D. R.; Murzin, A. G. A protein catalytic framework with an N-terminal nucleophile is capable of selfactivation. Nature, 1995, 378, 416-419.
59. Ditzel, L.; Stock, D.; Lowe, J. Structural investigation of proteasome inhibition. Biol. Chem., 1997, 378, 239-347.
60. Chen, P.; Hochstrasser, M. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell, 1996, 86, 961-972.
61. Jager, S.; Groll, M.; Huber, R.; Wolf, D. H.; Heinemeyer, W. Proteasome beta-type subunits: unequal roles of propeptides in core particle maturation and a hierarchy of active site function. J. Mol. Biol., 1999, 291, 997-1013.
62. Arendt, C. S.; Hochstrasser, M. Eukaryotic 20S proteasome catalytic subunit propeptides prevent active site inactivation by Nterminal acetylation and promote particle assembly. EMBO J., 1999, 18, 3575-3585.
63. Groll, M.; Huber, R.; Potts, B. C. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J. Am. Chem. Soc., 2006, 128, 5136-5141.
64. Duggleby, H. J.; Tolley, S. P.; Hill, C.; Dodson, E. J.; Dodson, G.; Moody, P. C. Penicillin acylase has a single-amino-acid catalytic centre. Nature, 1995, 373, 264-268.
65. Gutfreund, H.; Sturtevant, J. M. The mechanism of chymotrypsincatalyzed reactions. Proc. Natl. Acad. Sci. USA, 1956, 42, 719-728.
66. Cassidy, C. S.; Lin, J.; Frey, P. A. A new concept for the mechanism of action of chymotrypsin: the role of the low-barrier hydrogen bond. Biochemistry, 1997, 36, 4576-4584.
67. Lin, J.; Cassidy, C. S.; Frey, P. A. Correlations of the basicity of His 57 with transition state analogue binding, substrate reactivity, and the strength of the low-barrier hydrogen bond in chymotrypsin. Biochemistry, 1998, 37, 11940-11948.
68. Tanford, C. The interpretation of hydrogen ion titration curves of proteins. Adv. Protein Chem., 1962, 17, 69-165.
69. Groll, M.; McArthur, K. A.; Macherla, V. R.; Manam, R. R.; Potts, B. C. Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition. J. Med. Chem., 2009, 52, 5420-5428.
70. Schechter, I.; Berger, A. On the active site of proteases. 3. Mapping the active site of papain; specific peptide inhibitors of papain. Biochem. Biophys. Res. Commun., 1968, 32, 898-902.
71. Groll, M.; Nazif, T.; Huber, R.; Bogyo, M. Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome. Chem. Biol., 2002, 9, 655-662.
72. Nazif, T.; Bogyo, M. Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors. Proc. Natl. Acad. Sci. USA, 2001, 98, 2967-2972.
73. Hilt, W.; Wolf, D. H. Proteasomes: destruction as a programme. Trends Biochem. Sci., 1996, 21, 96-102.
74. Dick, T. P.; Nussbaum, A. K.; Deeg, M.; Heinemeyer, W.; Groll, M.; Schirle, M.; Keilholz, W.; Stevanovic, S.; Wolf, D. H.; Huber, R.; Rammensee, H. G.; Schild, H. Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J. Biol. Chem., 1998, 273, 25637-25646.
75. Emmerich, N. P.; Nussbaum, A. K.; Stevanovic, S.; Priemer, M.; Toes, R. E.; Rammensee, H. G.; Schild, H. The human 26 S and 20 S proteasomes generate overlapping but different sets of peptide fragments from a model protein substrate. J. Biol. Chem., 2000, 275, 21140-21148.
76. Groll, M.; Gotz, M.; Kaiser, M.; Weyher, E.; Moroder, L. TMC-95- based inhibitor design provides evidence for the catalytic versatility of the proteasome. Chem. Biol., 2006, 13, 607-614.
77. Coux, O.; Tanaka, K.; Goldberg, A. L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem., 1996, 65, 801-847.
78. Kisselev, A. F.; Goldberg, A. L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol., 2001, 8, 739-758.
79. Groll, M.; Huber, R. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim. Biophys. Acta, 2004, 1695, 33-44.
80. Loidl, G.; Groll, M.; Musiol, H. J.; Huber, R.; Moroder, L. Bivalency as a principle for proteasome inhibition. Proc. Natl. Acad. Sci. USA, 1999, 96, 5418-5422.
81. Loidl, G.; Groll, M.; Musiol, H. J.; Ditzel, L.; Huber, R.; Moroder, L. Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes. Chem. Biol., 1999, 6, 197-204.
82. Vinitsky, A.; Michaud, C.; Powers, J. C.; Orlowski, M. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry, 1992, 31, 9421-9428.
83. Hines, J.; Groll, M.; Fahnestock, M.; Crews, C. M. Proteasome inhibition by fellutamide B induces nerve growth factor synthesis. Chem. Biol., 2008, 15, 501-512.
84. Bogyo, M.; McMaster, J. S.; Gaczynska, M.; Tortorella, D.; Goldberg, A. L.; Ploegh, H. Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc. Natl. Acad. Sci. USA, 1997, 94, 6629-6634.
85. Adams, J.; Palombella, V. J.; Sausville, E. A.; Johnson, J.; Destree, A.; Lazarus, D. D.; Maas, J.; Pien, C. S.; Prakash, S.; Elliott, P. J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res., 1999, 59, 2615-2622.
86. Groll, M.; Berkers, C. R.; Ploegh, H. L.; Ovaa, H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure, 2006, 14, 451-456.
87. Walker, B.; Lynas, J. F. Strategies for the inhibition of serine proteases. Cell Mol. Life Sci., 2001, 58, 596-624.
88. Transue, T. R.; Krahn, J. M.; Gabel, S. A.; DeRose, E. F.; London, R. E. X-ray and NMR characterization of covalent complexes of trypsin, borate, and alcohols. Biochemistry, 2004, 43, 2829-2839.
89. London, R. E.; Gabel, S. A. Formation of a trypsin-borate-4- aminobutanol ternary complex. Biochemistry, 2002, 41, 5963-5967.
90. London, R. E.; Gabel, S. A. Development and evaluation of a boronate inhibitor of gamma-glutamyl transpeptidase. Arch. Biochem. Biophys., 2001, 385, 250-258.
91. Weber, P. C.; Lee, S. L.; Lewandowski, F. A.; Schadt, M. C.; Chang, C. W.; Kettner, C. A. Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs. Biochemistry, 1995, 34, 3750-3757.
92. Richardson, P. G.; Sonneveld, P.; Schuster, M. W.; Irwin, D.; Stadtmauer, E. A.; Facon, T.; Harousseau, J. L.; Ben-Yehuda, D.; Lonial, S.; Goldschmidt, H.; Reece, D.; San-Miguel, J. F.; Blade, J.; Boccadoro, M.; Cavenagh, J.; Dalton, W. S.; Boral, A. L.; Esseltine, D. L.; Porter, J. B.; Schenkein, D.; Anderson, K. C. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med., 2005, 352, 2487-2498.
93. San Miguel, J. F.; Schlag, R.; Khuageva, N. K.; Dimopoulos, M. A.; Shpilberg, O.; Kropff, M.; Spicka, I.; Petrucci, M. T.; Palumbo, A.; Samoilova, O. S.; Dmoszynska, A.; Abdulkadyrov, K. M.; Schots, R.; Jiang, B.; Mateos, M. V.; Anderson, K. C.; Esseltine, D. L.; Liu, K.; Cakana, A.; van de Velde, H.; Richardson, P. G. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med., 2008, 359, 906-917.
94. Fisher, R. I.; Bernstein, S. H.; Kahl, B. S.; Djulbegovic, B.; Robertson, M. J.; de Vos, S.; Epner, E.; Krishnan, A.; Leonard, J. P.; Lonial, S.; Stadtmauer, E. A.; O'Connor, O. A.; Shi, H.; Boral, A. L.; Goy, A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol., 2006, 24, 4867-4874.
95. Sanchez, E.; Li, M.; Steinberg, J. A.; Wang, C.; Shen, J.; Bonavida, B.; Li, Z. W.; Chen, H.; Berenson, J. R. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br. J. Haematol., 2010, 148, 569-581.
96. Piva, R.; Ruggeri, B.; Williams, M.; Costa, G.; Tamagno, I.; Ferrero, D.; Giai, V.; Coscia, M.; Peola, S.; Massaia, M.; Pezzoni, G.; Allievi, C.; Pescalli, N.; Cassin, M.; di Giovine, S.; Nicoli, P.; de Feudis, P.; Strepponi, I.; Roato, I.; Ferracini, R.; Bussolati, B.; Camussi, G.; Jones-Bolin, S.; Hunter, K.; Zhao, H.; Neri, A.; Palumbo, A.; Berkers, C.; Ovaa, H.; Bernareggi, A.; Inghirami, G. CEP-18770: A novel, orally active proteasome inhibitor with a tumor- selective pharmacologic profile competitive with bortezomib. Blood, 2008, 111, 2765-2775.
97. Meng, L.; Kwok, B. H.; Sin, N.; Crews, C. M. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res., 1999, 59, 2798-2801.
98. Groll, M.; Kim, K. B.; Kairies, N.; Huber, R.; Crews, C. M. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of alpha ',beta '-epoxyketone proteasome inhibitors. J. Am. Chem. Soc., 2000, 122, 1237-1238.
99. O'Connor, O. A.; Stewart, A. K.; Vallone, M.; Molineaux, C. J.; Kunkel, L. A.; Gerecitano, J. F.; Orlowski, R. Z. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin. Cancer Res., 2009, 15, 7085-7091.
100. Koguchi, Y.; Kohno, J.; Nishio, M.; Takahashi, K.; Okuda, T.; Ohnuki, T.; Komatsubara, S. TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities. J. Antibiot. (Tokyo), 2000, 53, 105-109.
101. Kohno, J.; Koguchi, Y.; Nishio, M.; Nakao, K.; Kuroda, M.; Shimizu, R.; Ohnuki, T.; Komatsubara, S. Structures of TMC-95A-D: novel proteasome inhibitors from Apiospora montagnei sacc. TC 1093. J. Org. Chem., 2000, 65, 990-995.
102. Groll, M.; Koguchi, Y.; Huber, R.; Kohno, J. Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor. J. Mol. Biol., 2001, 311, 543-548.
103. Kaiser, M.; Groll, M.; Renner, C.; Huber, R.; Moroder, L. The core structure of TMC-95A is a promising lead for reversible proteasome inhibition. Angew. Chem. Int. Ed. Engl., 2002, 41, 780-783.
104. Kaiser, M.; Siciliano, C.; Assfalg-Machleidt, I.; Groll, M.; Milbradt, A. G.; Moroder, L. Synthesis of a TMC-95A ketomethylene analogue by cyclization via intramolecular Suzuki coupling. Org. Lett., 2003, 5, 3435-3437.
105. Kaiser, M.; Milbradt, A.; Siciliano, C.; Assfalg-Machleidt, I.; Machleidt, W.; Groll, M.; Renner, C.; Moroder, L. TMC-95A analogues with endocyclic biphenyl ether group as proteasome inhibitors. Chem. Biodiv., 2004, 1, 161-173.
106. Kaiser, M.; Groll, M.; Siciliano, C.; Assfalg-Machleidt, I.; Weyher, E.; Kohno, J.; Milbradt, A. G.; Renner, C.; Huber, R.; Moroder, L. Binding mode of TMC-95A analogues to eukaryotic 20S proteasome. ChemBioChem, 2004, 5, 1256-1266.
107. Basse, N.; Piguel, S.; Papapostolou, D.; Ferrier-Berthelot, A.; Richy, N.; Pagano, M.; Sarthou, P.; Sobczak-Thepot, J.; Reboud- Ravaux, M.; Vidal, J. Linear TMC-95-based proteasome inhibitors. J. Med. Chem., 2007, 50, 2842-2850.
108. Groll, M.; Gallastegui, N.; Maréchal, X.; Le Ravalec, V.; Basse, N.; Richy, N.; Genin, E.; Huber, R.; Moroder, L. J., V. Reboud-Ravaux, M. 20S proteasome inhibition: designing non-covalent linear peptide mimics of the natural product TMC-95A. ChemMed- Chem., 2010, 5(10),1701-1705
109. Basse, N.; Papapostolou, D.; Pagano, M.; Reboud-Ravaux, M.; Bernard, E.; Felten, A. S.; Vanderesse, R. Development of lipopeptides for inhibiting 20S proteasomes. Bioorg. Med. Chem. Lett., 2006, 16, 3277-3281.
110. Formicola, L.; Marechal, X.; Basse, N.; Bouvier-Durand, M.; Bonnet- Delpon, D.; Milcent, T.; Reboud-Ravaux, M.; Ongeri, S. Novel fluorinated pseudopeptides as proteasome inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 83-86.
111. Basse, N.; Montes, M.; Marechal, X.; Qin, L.; Bouvier-Durand, M.; Genin, E.; Vidal, J.; Villoutreix, B. O.; Reboud-Ravaux, M. Novel organic proteasome inhibitors identified by virtual and in vitro screening. J. Med. Chem., 2010, 53, 509-513.
112. Blackburn, C.; Gigstad, K. M.; Hales, P.; Garcia, K.; Jones, M.; Bruzzese, F. J.; Barrett, C.; Liu, J. X.; Soucy, T. A.; Sappal, D. S.; Bump, N.; Olhava, E. J.; Fleming, P.; Dick, L. R.; Tsu, C.; Sintchak, M. D.; Blank, J. L. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit. Biochem. J., 2010, 430, 461-476.
113. Groll, M.; Huber, R.; Moroder, L. The persisting challenge of selective and specific proteasome inhibition. J. Pept. Sci., 2009, 15, 58-66.
114. Genin, E.; Reboud-Ravaux, M.; Vidal, J. Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry. Curr. Top. Med. Chem., 2010, 10, 232-256.
115. Groll, M.; Schellenberg, B.; Bachmann, A. S.; Archer, C. R.; Huber, R.; Powell, T. K.; Lindow, S.; Kaiser, M.; Dudler, R. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature, 2008, 452, 755-758.
116. Clerc, J.; Florea, B. I.; Kraus, M.; Groll, M.; Huber, R.; Bachmann, A. S.; Dudler, R.; Driessen, C.; Overkleeft, H. S.; Kaiser, M. Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines. ChemBioChem, 2009, 10, 2638-2643.
117. Clerc, J.; Groll, M.; Illich, D. J.; Bachmann, A. S.; Huber, R.; Schellenberg, B.; Dudler, R.; Kaiser, M. Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition. Proc. Natl. Acad. Sci. USA, 2009, 106, 6507-6512.
118. Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Velankar, M.; Mitsiades, C.; Mitsiades, N.; Yasui, H.; Letai, A.; Ovaa, H.; Berkers, C.; Nicholson, B.; Chao, T. H.; Neuteboom, S. T.; Richardson, P.; Palladino, M. A.; Anderson, K. C. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell, 2005, 8, 407-419.
119. Chauhan, D.; Singh, A.; Brahmandam, M.; Podar, K.; Hideshima, T.; Richardson, P.; Munshi, N.; Palladino, M. A.; Anderson, K. C. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood, 2008, 111, 1654-1664.
120. Lam, K. S.; Lloyd, G. K.; Neuteboom, S. T.; Palladino, M. A.; Sethna, K. M.; Spear, M. A.; Potts, B. C. From Natural Product to Clinical Trials: NPI-0052 (Salinosporamide A), a Marine Actinomycete- Derived Anticancer Agent. Royal Society of Chemistry: Cambridge, UK, Biomolecular Science, 2010; p 355-373.
121. Townsend, A. R.; Millward, M.; Price, T.; Mainwaring, P.; Spencer, A.; Longenecker, A.; Palladino, M. A.; Lloyd, G. K.; Spear, M. A.; Padrik, P. Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm). J. Clin. Oncol., 2009, 27, 3582.
122. Omura, S.; Matsuzaki, K.; Fujimoto, T.; Kosuge, K.; Furuya, T.; Fujita, S.; Nakagawa, A. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J. Antibiot. (Tokyo), 1991, 44, 117-118.
123. Asai, A.; Tsujita, T.; Sharma, S. V.; Yamashita, Y.; Akinaga, S.; Funakoshi, M.; Kobayashi, H.; Mizukami, T. A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay. Biochem. Pharmacol., 2004, 67, 227-234.
124. Groll, M.; Larionov, O. V.; Huber, R.; de Meijere, A. Inhibitorbinding mode of homobelactosin C to proteasomes: new insights into class I MHC ligand generation. Proc. Natl. Acad. Sci.USA, 2006, 103, 4576-4579.
125. Omura, S.; Fujimoto, T.; Otoguro, K.; Matsuzaki, K.; Moriguchi, R.; Tanaka, H.; Sasaki, Y. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J. Antibiot. (Tokyo), 1991, 44, 113-116.
126. Corey, E. J.; Li, W. D. Total synthesis and biological activity of lactacystin, omuralide and analogs. Chem. Pharm. Bull. (Tokyo), 1999, 47, 1-10.
127. Reed, K. A.; Manam, R. R.; Mitchell, S. S.; Xu, J.; Teisan, S.; Chao, T. H.; Deyanat-Yazdi, G.; Neuteboom, S. T.; Lam, K. S.; Potts, B. C. Salinosporamides D-J from the marine actinomycete Salinispora tropica, bromosalinosporamide, and thioester derivatives are potent inhibitors of the 20S Proteasome. J. Nat. Prod., 2007, 70, 269-276.
128. Manam, R. R.; Macherla, V. R.; Tsueng, G.; Dring, C. W.; Weiss, J.; Neuteboom, S. T.; Lam, K. S.; Potts, B. C. Antiprotealide is a natural product. J. Nat. Prod., 2009, 72, 295-297.
129. Stadler, M.; Bitzer, J.; Mayer-Bartschmid, A.; Muller, H.; Benet- Buchholz, J.; Gantner, F.; Tichy, H. V.; Reinemer, P.; Bacon, K. B. Cinnabaramides A-G: analogues of lactacystin and salinosporamide from a terrestrial streptomycete. J. Nat. Prod., 2007, 70, 246-252.
130. Tomoda, H.; Omura, S. Lactacystin, a proteasome inhibitor: discovery and its application in cell biology. Yakugaku Zasshi, 2000, 120, 935-949.
131. Fenteany, G.; Standaert, R. F.; Reichard, G. A.; Corey, E. J.; Schreiber, S. L. A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. Proc. Natl. Acad. Sci. USA, 1994, 91, 3358-3362.
132. Dick, L. R.; Cruikshank, A. A.; Grenier, L.; Melandri, F. D.; Nunes, S. L.; Stein, R. L. Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone. J. Biol. Chem., 1996, 271, 7273-7276.
133. Dick, L. R.; Cruikshank, A. A.; Destree, A. T.; Grenier, L.; McCormack, T. A.; Melandri, F. D.; Nunes, S. L.; Palombella, V. J.; Parent, L. A.; Plamondon, L.; Stein, R. L. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J. Biol. Chem., 1997, 272, 182-188.
134. Macherla, V. R.; Mitchell, S. S.; Manam, R. R.; Reed, K. A.; Chao, T. H.; Nicholson, B.; Deyanat-Yazdi, G.; Mai, B.; Jensen, P. R.; Fenical, W. F.; Neuteboom, S. T.; Lam, K. S.; Palladino, M. A.; Potts, B. C. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J. Med. Chem., 2005, 48, 3684-3687.
135. Masse, C. E.; Morgan, A. J.; Adams, J.; Panek, J. S. Syntheses and biological evaluation of (+)-lactacystin and analogs. Eur. J. Org. Chem., 2000, 2513-2528.
136. Balskus, E. P.; Jacobsen, E. N. Alpha,beta-unsaturated beta-silyl imide substrates for catalytic, enantioselective conjugate additions: a total synthesis of (+)-lactacystin and the discovery of a new proteasome inhibitor. J. Am. Chem. Soc., 2006, 128, 6810-6812.
137. Groll, M.; Balskus, E. P.; Jacobsen, E. N. Structural analysis of spiro beta-lactone proteasome inhibitors. J. Am. Chem. Soc., 2008, 130, 14981-14983.
138. Shah, I. M.; Lees, K. R.; Pien, C. P.; Elliott, P. J. Early clinical experience with the novel proteasome inhibitor PS-519. Br. J. Clin. Pharmacol. 2002, 54, 269-276.
139. Potts, B. C.; Lam, K. S. Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide A (NPI-0052) and other salinosporamides. Mar. Drugs, 2010, 8, 835-880.
140. Reddy, L. R.; Fournier, J. F.; Reddy, B. V. S.; Corey, E. J. An efficient, stereocontrolled synthesis of a potent omuralidesalinosporin hybrid for selective proteasome inhibition. J. Am. Chem. Soc., 2005, 127, 8974-8976.
141. McGlinchey, R. P.; Nett, M.; Eustaquio, A. S.; Asolkar, R. N.; Fenical, W.; Moore, B. S. Engineered biosynthesis of antiprotealide and other unnatural salinosporamide proteasome inhibitors. J. Am. Chem. Soc., 2008, 130, 7822-7823.
142. Nett, M.; Gulder, T. A.; Kale, A. J.; Hughes, C. C.; Moore, B. S. Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica. J. Med. Chem., 2009, 52, 6163-6167.
143. Kisselev, A. F.; Callard, A.; Goldberg, A. L. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J. Biol. Chem., 2006, 281, 8582-8590.
144. Williams, P. G.; Buchanan, G. O.; Feling, R. H.; Kauffman, C. A.; Jensen, P. R.; Fenical, W. New cytotoxic salinosporamides from the marine actinomycete Salinispora tropica. J. Org. Chem., 2005, 70, 6196-6203.
145. Macherla, V.; Potts, B. C.; Manam, R. R.; McArthur, K. A.; Chao, T.-H.; Neuteboom, S. T. C. Salinosporamide derivatives as proteasome inhibitors. WO 2009/140287 A1 2009.
146. Braun, H. A.; Umbreen, S.; Groll, M.; Kuckelkorn, U.; Mlynarczuk, I.; Wigand, M. E.; Drung, I.; Kloetzel, P. M.; Schmidt, B. Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines. J. Biol. Chem., 2005, 280, 28394-28401.
147. Chao, T.-H.; Wahlgren, B.; Obaidat, A.; Weiss, J.; Manam, R. R.; McArthur, K. A.; Macherla, V. R.; Palladino, M. A.; Hagenbuch, B.; Potts, B. C.; Enna, S. J.; Lloyd, G. K.; Neuteboom, S. T. C. The Chlorine Leaving Group of the Proteasome Inhibitor NPI-0052 is Key to its Potency, Durability of Proteasome Inhibition and May Influence its Efflux Rate from Tumor Cells. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research 2009, Abstract nr 4539.
148. Miller, C.P.; Manton, C.A.; Hale, R.; Debose, L.; Macherla, V.R.; Potts, B.C.; Palladino, M.A.; Chandra, J. Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs. Chem. Biol. Interact., 2011 Aug. 16.[Epub ahead of print].
149. Eustaquio, A. S.; Moore, B. S. Mutasynthesis of fluorosalinosporamide, a potent and reversible inhibitor of the proteasome. Angew. Chem. Int. Ed. Engl., 2008, 47, 3936-3938.
150. Potts, B. C.; Macherla, V. R.; Mitchell, S. S.; Manam, R. R.; Reed, K. A.; Lam, K. S.; Neuteboom, S. T. C.; Chao, T.-H.; Nicholson, B.; Billstrom, C. [3.2.0] Heterocyclic compounds and methods of using the same. WO 2006/028525 A2 2006.
151. Palladino, M. A.; Chao, T.; Neuteboom, S. T.; Spear, M.; Ma, W.; Albitar, M. Preclinical and clinical monitoring of cell-and circulating plasma specific proteasome biomarkers after treatment with the proteasome inhibitor NPI-0052. Eur. J. Cancer, EJC Suppl., 2008, 6, Abstract 235.
152. Singh, A. V.; Palladino, M. A.; Lloyd, G. K.; Potts, B. C.; Chauhan, D.; Anderson, M. D. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Brit. J. Haematol., 2010, 149, 550-559.
153. Buglio, D.; Georgios, G.; Chao, T.-H.; Neuteboom, S.; Palladino, M. A.; Younes, A. A novel proteasome inhibitor, NPI-0052 is active in Hodgkin and mantle cell lymphoma cell lines. Proc. Am. Assoc. Cancer Res., 2007, 1454.
154. Roccaro, A. M.; Leleu, X.; Sacco, A.; Jia, X.; Melhem, M.; Moreau, A. S.; Ngo, H. T.; Runnels, J.; Azab, A.; Azab, F.; Burwick, N.; Farag, M.; Treon, S. P.; Palladino, M. A.; Hideshima, T.; Chauhan, D.; Anderson, K. C.; Ghobrial, I. M. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood, 2008, 111, 4752-4763.
155. Miller, C. P.; Ban, K.; Dujka, M. E.; McConkey, D. J.; Munsell, M.; Palladino, M.; Chandra, J. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood, 2007, 110, 267-277.
156. Ruiz, S.; Krupnik, Y.; Keating, M.; Chandra, J.; Palladino, M.; McConkey, D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol. Cancer Ther., 2006, 5, 1836-1843.
157. Cusack, J. C., Jr.; Liu, R.; Xia, L.; Chao, T. H.; Pien, C.; Niu, W.; Palombella, V. J.; Neuteboom, S. T.; Palladino, M. A. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin. Cancer Res., 2006, 12, 6758-6764.
158. Sloss, C. M.; Wang, F.; Liu, R.; Xia, L.; Houston, M.; Ljungman, D.; Palladino, M. A.; Cusack, J. C., Jr. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFRindependent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin. Cancer Res., 2008, 14, 5116-5123.
159. Hofmeister, C. C.; Richardson, P.; Zimmerman, T.; Spear, M. A.; Palladino, M. A.; Longenecker, A. M.; Cropp, G. F.; Lloyd, G. K.; Hannah, A. L.; Anderson K. Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/ refractory multiple myeloma (r/r MM). J. Clin. Onc., 2009, 27, 8505.
160. Hillebrand, S.; Guth, O.; Wiese, W.-B.; Kunz, K.; Ullmann, A.; Mattes, A.; Schreier, P.; Wachendorff-Neumann, U.; Kuck, K.-H.; Lösel, P.; Malsam, O.; Reinemer, P.; Stadler, M.; Seip, S.; Mayer- Bartschmid, A.; Müller, H.; Bacon, K. WO 2006/005551 A1. Intl. Pub., 2006.
161. Vijay-Kumar, S.; Bugg, C. E.; Cook, W. J. Structure of ubiquitin refined at 1.8 A resolution. J. Mol. Biol., 1987, 194, 531-544.
162. Lee, I.; Schindelin, H. Structural insights into E1-catalyzed ubiquitin activation and transfer to conjugating enzymes. Cell, 2008, 134, 268-278.
163. Olsen, S. K.; Capili, A. D.; Lu, X.; Tan, D. S.; Lima, C. D. Active site remodelling accompanies thioester bond formation in the SUMO E1. Nature, 2010, 463, 906-912.
164. Lu, X.; Olsen, S. K.; Capili, A. D.; Cisar, J. S.; Lima, C. D.; Tan, D. S. Designed semisynthetic protein inhibitors of Ub/Ubl E1 activating enzymes. J. Am. Chem. Soc., 2010, 132, 1748-1749.
165. Sakata, E.; Satoh, T.; Yamamoto, S.; Yamaguchi, Y.; Yagi-Utsumi, M.; Kurimoto, E.; Tanaka, K.; Wakatsuki, S.; Kato, K. Crystal structure of UbcH5b approximately ubiquitin intermediate: insight into the formation of the self-assembled E2 approximately Ub conjugates. Structure, 2010, 18, 138-147.
166. Kamadurai, H. B.; Souphron, J.; Scott, D. C.; Duda, D. M.; Miller, D. J.; Stringer, D.; Piper, R. C.; Schulman, B. A. Insights into ubiquitin transfer cascades from a structure of a UbcH5B approximately ubiquitin-HECT(NEDD4L) complex. Mol. Cell, 2009, 36, 1095-1102.
167. Yoshikawa, A.; Sato, Y.; Yamashita, M.; Mimura, H.; Yamagata, A.; Fukai, S. Crystal structure of the NEMO ubiquitin-binding domain in complex with Lys 63-linked di-ubiquitin. FEBS Lett., 2009, 583, 3317-3322.
168. Koegl, M.; Hoppe, T.; Schlenker, S.; Ulrich, H. D.; Mayer, T. U.; Jentsch, S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell, 1999, 96, 635-644.
169. Komander, D.; Clague, M. J.; Urbe, S. Breaking the chains: structure and function of the deubiquitinases. Nat. Rev. Mol. Cell Biol., 2009, 10, 550-563.
170. Groll, M.; Huber, R. Substrate access and processing by the 20S proteasome core particle. Int. J. Biochem. Cell Biol., 2003, 35, 606-616.
171. Hu, G.; Lin, G.; Wang, M.; Dick, L.; Xu, R. M.; Nathan, C.; Li, H. Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate. Mol. Microbiol., 2006, 59, 1417-1428.
172. Elofsson, M.; Splittgerber, U.; Myung, J.; Mohan, R.; Crews, C. M. Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones. Chem. Biol., 1999, 6, 811-822.